Flavonoids: A versatile source of anticancer drugs

Pharmacognosy Reviews

Volumn 5, Issue 9, 2011, Pages 1-12

  Chahar, Maheep K ^a   Sharma, Neelu ^a   Dobhal, Mahabeer P ^a   Joshi, Yogesh C ^a  

^a UNIVERSITY OF RAJASTHAN   (India)

Author keywords

Apoptosis; estrogens receptor; flavonoids; mammary cancer; prostate cancer

Indexed keywords

ANTHOCYANIN; APIGENIN; BIOCHANIN A; CATECHIN; CHALCONE; CHRYSIN; CHRYSOERIOL; CISPLATIN; CURCUMIN; DAIDZEIN; DIOSMETIN; EPICATECHIN; FLAVANONE; FLAVONE; FLAVONOID; FLAVOPIRIDOL; GENISTEIN; GLYCITEIN; INDIRUBIN; ISOFLAVONE; KAEMPFEROL; LUTEOLIN; MITOFLAXONE; MYRICETIN; NOBILETIN; QUERCETIN; SILIBININ; SILYMARIN; UNCLASSIFIED DRUG; XANTHONE 4 ACETIC ACID;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL STRAIN HL 60; CELL STRAIN HT29; CELL STRAIN K 562; CELL STRAIN LNCAP; CELL STRAIN MCF 7; CHEMOPROPHYLAXIS; COLON CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; LEUKEMIA; LIPID PEROXIDATION; LUNG CANCER; METABOLIC ACTIVATION; MOUTH CANCER; NONHUMAN; PROSTATE CANCER; REVIEW; THYROID CANCER; TREATMENT RESPONSE;

EID: 79955113135     PISSN: 09737847     EISSN: 09762787     Source Type: Journal    
DOI: 10.4103/0973-7847.79093     Document Type: Review

References (131)

1. Bravo L. Polyphenols: Chemistry, dietary sources, metabolism and nutritional significance. Nutr Rev 1998;56:317-33. (Pubitemid 28532456)
2. Hodek P, Trefil P, Stiborova M. Flavonoids- Potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 2002;139:1-21. (Pubitemid 34135994)
3. Kuhnau J. The flavonoids. A class of semi-essential food components:their role in human nutrition. World Rev Nutr Diet 1976;24:117-91.
4. Obdulio BG, Julian C, Francisco RM, Ana O, Jose AD. Uses and properties of Citrus flavonoids. J Agric Food Chem 1997;45:4505-15.
5. Manthey JA, Guthrie N, Grohmann K. Biological properties of Citrus flavonoids Pertaining to cancer and inflammation. Curr Med Chem 2001;8:135-53. (Pubitemid 32421562)
6. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
7. Middleton EJ, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer. Pharmacol Rev 2000;52:673-751.
8. Galati G, Teng S, Moridani MY, Chan TS, O Brien PJ. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metabol Drug Interact 2000;17:311-49. (Pubitemid 32047540)
9. Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 2001;21:381-406. (Pubitemid 32695277)
10. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention Flavonoids and isoflavonoids. Pharmacol Ther 2001;90:157-77. (Pubitemid 32913477)
11. Weinberg RA. Oncogenes and the Molecular Origins of cancer.: Cold Spring Harbor Laboratory. New York: Cold Spring Harbor; 1989.
12. Pimentel E. Oncogenes. 2nd ed. Florida: CRC Press; 1989.
13. Hunter T, Cooper A. The Enzymes. In: Boyer PD, Krebs EG, editors. Vol. 17. Florida: Academic Press; 1987. p. 191-246.
14. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Ann Rcv Biorhnn 1987;56:881-914.
15. Yarden T, Ullrich A. Growth factor receptor tyrosine kinases. Am Rcv Biorhnn 1988;57:443-78.
16. Geahlen RL, Harrison ML. In: Kemp BE, editor. Peptides and Protein Phosphorylation. Florida: CRC Press; 1989. p. 239-53.
17. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
18. Nijhoff WA, Groen GM, Peters WH. Induction of rat hepatic and intestinal glutathione S-transferases and glutathione by dietary naturally occuring anticarcinogens. Int J Oncol 1993;3:1131-9. (Pubitemid 23361374)
19. Vander LE, Roelofs HM, Nagengast FM, Peters WH. Induction of rat hepatic and intestinal UDP-glucuronosyl transferases by naturally occurring dietary anticarcinogens. Carcinogenesis 2003;24:1651-6. (Pubitemid 37304670)
20. Steele VE, Kelloff GJ, Balentine D, Boone CW, Mehta R, Bagheri D, et al. Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. Carcinogenesis 2000;21:67-3.
21. Marchand LL, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. Intake of flavonoids and lung cancer. J Natl Cancer Inst 2000;92:154-60. (Pubitemid 30089873)
22. Tsyrlov IB, Mikhailenko VM, Gelboin HV. Isozyme- and speciesspecific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids. Biochim Biophys Acta 1994;1205:325-35. (Pubitemid 24115026)
23. Bu-Abbas A, Clifford MN, Walker R, Ioannides C. Contribution of caffeine and flavanols in the induction of hepatic Phase II activities by green tea. Food Chem Toxicol 1998;36:617-21. (Pubitemid 28369888)
24. Sun XY, Plouzek CA, Henry JP,Wang TT, Phang JM. Increased UDP-glucuronosyl transferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res 1998;58:2379-84. (Pubitemid 28252698)
25. Chang WS, Lee YJ, Lu FJ, Chiang HC. Inhibitory effects of flavonoids on xanthine oxidase. Anticancer Res 1993;13: 2165-70.
26. Mutoh M, Takahashi M, Fukuda K, Komatsu H, Enya T, Matsushima HY, et al. Suppression by flavonoids of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells: Structure-activity relationship. Jpn J Cancer Res 2000;91:686-91. (Pubitemid 30612352)
27. Tanaka T, Makita H, Kawabata K, Mori H, Kakumoto M, Satoh K, et al. Chemoprevention of azoxymethane-induced rat colon carcinogenesis By the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 1997;18:957-65. (Pubitemid 28132340)
28. Tanaka T, Makita H, Ohnishi M, Mori H, Satoh K, Hara A, et al. Chemoprevention of 4- nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Cancer Res 1997;57:246-52. (Pubitemid 27036601)
29. Makita H, Tanaka T, Fujitsuka H, Tatematsu N, Satoh K, Hara A, et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin. Cancer Res 1996;56:4904-9. (Pubitemid 26374427)
30. Senderowicz AM. Flavopiridol. The first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999;17: 313-20. (Pubitemid 30037961)
31. Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001;15:1-9. (Pubitemid 32124064)
32. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDAMB 468:Induction of G1 arrest through an increase in Cip1/ p21 concomitant with a decrease in kinase activity of cyclindependent kinases and associated cyclins. Clin Cancer Res 1998;4:1055-64. (Pubitemid 28183409)
33. Choi JA, Kim JY, Lee JY, Kang CM, Kwon HJ, Yoo YD, et al. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int J Oncol 2001;19:837-44.
34. Casagrande F, Darbon JM. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol 2001;61:1205-15. (Pubitemid 32375112)
35. Wang HK. The therapeutic potential of flavonoids. Expert Opin Invest Drugs 2000;9:2103-19.
36. Sakagami H, Jiang Y, Kusama K, Atsumi T, Ueha T, Toguchi M, et al. Induction of apoptosis by flavones, flavonols (3-hydroxyflavones) and isoprenoid-substituted flavonoids in human oral tumor cell lines. Anticancer Res 2000;20:271-7. (Pubitemid 30189765)
37. Yin F, Giuliano AE, Van Herle AJ. Signal pathways involved in apigenin inhibition of Growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res 1999;19:4297-303.
38. Wenzel U, Kuntz S, Brendel MD, Daniel H, Daniel H. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 2000;60:3823-31. (Pubitemid 32204574)
39. De Vincenzo R, Ferlini C, Distefano M, Gaggini C, Riva A, Bombardelli E, et al. In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother Pharmacol 2000;46:305-12.
40. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related Flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL- 60 cells. Eur J Cancer 1999;35:1517-25.
41. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7:39-58. (Pubitemid 30395448)
42. Sukardiman, Darwanto A, Tanjung M, Darmadi MO. Cytotoxic mechanism of flavonoid from Temu Kunci (Kaempferia pandurata) in cell culture of human mammary carcinoma. Clin Hemorheol Microcirc 2000;23:185-90. (Pubitemid 32274603)
43. Lee WR, Shen SC, Lin HY, Hou WC, Yang LL, Chen YC. Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca(2+)-dependent endonuclease. Biochem Pharmacol 2002;63:225-36.
44. Rong Y, Yang EB, Zhang K, Mack P. Quercetin-induced apoptosis in the monoblastoid cell line U937 in vitro and the regulation of heat shock proteins expression. Anticancer Res 2000;20:4339-45. (Pubitemid 32141783)
45. Iwashita K, Kobori M, Yamaki K, Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem 2000;64:1813-20.
46. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997;90:4307-12. (Pubitemid 27508436)
47. Horak E, Smith K, Bromley L, LeJeune S, Greenall M, Lane D, et al. Oncogene 1991;6:2277-84.
48. Gross ME, Zorbas MA, Danels YJ, Garcia R, Wick GE, Olive M, et al. Cuncer Ru 1991;51:1452.
49. Chen SC, Chou CK, Wong FH, Chang CM, Hu CP. Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells. Cancer Res 1991;51:1898-903.
50. Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 1990;50:3934-9. (Pubitemid 20225609)
51. Weidner M, Peter S, Strokmeyer T, Hussnatter R, Ackermann R, Sies H. Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res 1990;50:4504-9. (Pubitemid 20230383)
52. Hirano T, Gotoh M, Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci 1994;55:1061-9.
53. Kuntz S, Wenzel U, Daniel H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity and apoptosis in human colon cancer cell lines. Eur J Nutr 1999;38:133-42. (Pubitemid 29352529)
54. Shi YQ, Fukai T, Sakagami H, Chang WJ, Yang PQ, Wang FP, et al. Cytotoxic flavonoids with isoprenoid groups from Morus mongolica. J Nat Prod 2001;64:181-8. (Pubitemid 32198342)
55. Fukai T, Sakagami H, Toguchi M, Takayama F, Iwakura I, Atsumi T, et al. Cytotoxic activity of low molecular weight polyphenols against human oral tumor cell lines. Anticancer Res 2000;20:2525-36. (Pubitemid 30614463)
56. Elattar TM, Virji AS. Effect of tea polyphenols on growth of oral squamous carcinoma cells in vitro. Anticancer Res 2000;20:3459-65.
57. Elattar TM, Virji AS. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res 2000;20:1733-38. (Pubitemid 30628195)
58. Pouget C, Lauthier F, Simon A, Fagnere C, Basly JP, Delage C, Chulia AJ. Flavonoids: Structural requirements for antiproliferative activity on breast cancer cells. Bioorg Med Chem Lett 2001;11:3095-7. (Pubitemid 33092000)
59. Han D, Tachibana H, Yamada K. Inhibition of environmental estrogen-induced proliferation of human breast carcinoma MCF- 7 cells by flavonoids. In vitro Cell Dev Biol Anim 2001;37:275-82. (Pubitemid 32751427)
60. Yin F, Giuliano AE, Van Herle AJ. Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid 1999;9:369-76. (Pubitemid 29206848)
61. Bai F, Matsui T, Ohtani-Fujita N, Matsukawa Y, Ding Y, Sakai T. Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells. FEBS Lett 1998;437:61-4. (Pubitemid 28498241)
62. Caltagirone S, Ranelletti FO, Rinelli A, Maggiano N, Colasante A, Musiani P, et al. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol 1997;17:51-9. (Pubitemid 127500820)
63. Knowles LM, Zigrossi DA, Tauber RA, Hightower C, Milner JA. Flavonoids Suppress Androgen independent human prostate tumor proliferation. Nutr Cancer 2000;38:116-22. (Pubitemid 32377951)
64. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 2001;46:98-107.
65. Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeorgou E, Gemetzi C, et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 2000;37:223-33.
66. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000;60:1051-9.
67. Kamei H, Hashimoto Y, Koide T, Kojima T, Hasegawa M. Antitumor effect of methanol extracts from red and white wines. Cancer Biother Radiopharm 1998;13:447-52. (Pubitemid 29069841)
68. Kuo SM, Morehouse HF, Lin CP. Effect of antiproliferative flavonoids on ascorbic acid accumulation in human colon adenocarcinoma cells. Cancer Lett 1997;116:131-7.
69. Kuo SM. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett 1996;110:41-8.
70. Chung HS, Chang LC, Lee SK, Shamon LA, van Breemen RB, Mehta RG, et al. Flavonoid constituents of Chorizanthe diffusa with potential cancer chemopreventive activity. J Agric Food Chem 1999;47:36-41. (Pubitemid 29179619)
71. Csokay B, Prajda N, Weber G, Olah E. Molecular mechanisms in the antiproliferative action of quercetin. Life Sci 1997;60: 2157-63. (Pubitemid 27244397)
72. Kamei H, Koide T, Kojimam T, Hasegawa M, Terabe K, Umeda T, et al. Flavonoid-mediated tumor growth suppression demonstrated by in vivo study. Cancer Biother Radiopharm 1996;11:193-6. (Pubitemid 26279401)
73. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 2000;87:595-600. (Pubitemid 30639822)
74. Yang M, Tanaka T, Hirose Y, Deguchi T, Mori H, Kawada Y. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl)nitrosamine- induced urinary-bladder carcinogenesis in male ICR mice. Int J Cancer 1997;73:719-24. (Pubitemid 127483070)
75. Siess MH, Le Bon AM, Canivenc-Lavier MC, Suschetet M. Mechanisms involved in the chemoprevention of flavonoids. Biofactors 2000;12:193-9. (Pubitemid 32107407)
76. Yang CS, Chung JY, Yang GY, Chhabra SK, Lee MJ. Tea and tea polyphenols in cancer prevention. J Nutr 2000;130:472S-8S. (Pubitemid 30073776)
77. Bracke M, Vyncke B, Opdenakker G, Foidart JM, De Pestel G, Mareel M. Effect of catechins and citrus flavonoids on invasion in vitro. Clin Exp Metastasis 1991;9:13-25.
78. Sato T, Koike L, Miyata Y, Hirata M, Mimaki Y, Sashida Y, et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080cells. Cancer Res 2002;62:1025-9. (Pubitemid 34160282)
79. Tatsuta M, Iishi H, Baba M, Yano H, Murata K, Mukai M, et al. Suppression by apigenin of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis 2000;18:657-62.
80. Parkin, DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of 25 major cancers in1990. Int J Cancer 1999;80: 827-41. (Pubitemid 29108856)
81. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31. (Pubitemid 24127628)
82. Markiewicz L., Garey J, Adlercreutz H, Gurpide E. In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol Biol 1993;45:399-405. (Pubitemid 23163017)
83. Setchell KD, Adlercreutz H. Mammalian lignans and phytoestrogens: Recent studies on their formation, metabolism and biological role in health and disease. In: Rowland IR, editor. Role of the Gut Flora in Toxicity and Cancer. London: London Academic; 1988. p. 315-45.
84. Martin PM, Horwitz KB, Ryan DS, McGuire WL. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 1978;103:1860-7. (Pubitemid 9052644)
85. Peterson G, Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer. Cell Growth Differ 1996;7:1345-51. (Pubitemid 26360683)
86. Wei H, Bowen R, Cai Q, Barnes S, Wang Y. Antioxidant and antipromotional effects of the soybean isoflavone genistein. Proc Soc Exp Biol Med 1995;208:124-30.
87. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5.
88. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 1989;49:5111-7. (Pubitemid 19239354)
89. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L. Genistein, a dietary Ingested isoflavone, inhibits cell proliferation and in vitro angiogenesis. Proc Natl Acad Sci USA 1993;90:6902-94.
90. Matsukawa Y, Marui N, Sakai T, Satomi Y, Yoshida M, Katsuhiko M, et al. Genistein arrests cell cycle progression at G2-M. Cancer Res 1993;53:1328-31. (Pubitemid 23097111)
91. Constantinou AI, Kamath N, Murley JS. Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Eur J Cancer 1998;34:1927-34. (Pubitemid 28535443)
92. Hong X, Schevzov G, Gunning P, Williams HM, Silink MA. Comparative Study of Growth-Inhibitory Effects of Isoflavones and Their Metabolites on Human Breast and Prostate Cancer Cell Lines. Nutr Cancer 2002;42:224-32. (Pubitemid 35253673)
93. Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J Ther 2001;8:333-44. (Pubitemid 33753130)
94. Pouget C, Fagnere C, Basly JP, Besson AE, Champavier Y, Habrioux G, et al. Synthesis and aromatase inhibitory activity of flavanones. Pharm Res 2002;19:286-91. (Pubitemid 34211845)
95. Jeong HJ, Shin YG, Kim IH, Pezzuto JM. Inhibition of aromatase activity by flavonoids. Arch Pharm Res 1999;22:309-12.
96. Ullah MF, Shamim U, Hanif S, Azmi AS, Hadi SM. Cellular DNA breakage by soy isoflavone genistein and its methylated structural analogue biochanin A. Mol Nutr Food Res 2009;53:1376-85.
97. Sohal RS, Weindruch R. Oxidative stress, caloric restriction and aging. Science 1996;273:59-63. (Pubitemid 26255420)
98. Baeuerle PA, Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997;65:111-37. (Pubitemid 27323247)
99. Stancovski I, Baltimore D. NF-êB Activation: The IêB Kinase Revealed. Cell 1997;91:299-302.
100. Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R. Effect of antioxidants on androgen-induced AP-1 and NFkappa B DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 1999;91:1227-32. (Pubitemid 29357189)
101. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio Drugs 2001;15:465-89. (Pubitemid 32783707)
102. Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of Stat 3 and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 2007;28:1463-70. (Pubitemid 47243538)
103. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999;96:7490-5. (Pubitemid 29299689)
104. Zi X, Zhang J, Agarwal R and Pollak M. Silibinin up-regulates insulin-like Growth factor-binding protein 3 expression and inhibits proliferation of androgen- independent prostate cancer cells. Cancer Res 2000;60:5617-20.
105. Sharma Y, Agarwal C, Singh AK, Agarwal R. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog 2001;30:224-36. (Pubitemid 32402178)
106. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999;18:7389-94. (Pubitemid 30032121)
107. Ueda H, Yamazaki C, Yamazaki M. Inhibitory effect of perilla leaf extract and luteolin on mouse skin tumor promotion. Biol Pharm Bull 2003;26:560-3. (Pubitemid 39663608)
108. Lim DY, Jeong Y, Tyner AL, Park JHY. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol 2007;292:G66-75. (Pubitemid 46090252)
109. Chiu FL, Lin JK. Down regulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 2007;68:61-71.
110. Aalinkeel R, Nair MPN, Sufrin G, Mahajan SD, Chadha KC, Chawda RP et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004;64:5311-21. (Pubitemid 39006551)
111. Vayalil PK, Mittal A, Katiyar SK. Proanthocyanidins from grape seeds inhibit Expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NF kappa B. Carcinogenesis 2004;25:987-95. (Pubitemid 38906615)
112. Vijayababu MR, Arunkumar A, Kanagaraj P, Venkataraman P, Krishnamoorthy G, Arunakaran J. Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol Cell Biochem 2006;287: 109-16. (Pubitemid 44057398)
113. Cummings J, Smyth JF. Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. Cancer Chemother Pharmacol 1989;24:269-72. (Pubitemid 19202948)
114. McKeage MJ, Kestell P, Denny WA, Baguley BC. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol 1991;28:409-13
115. Aitken RA, Bibby MC, Cooper PA, Double JA, Laws AL, Ritchie RB, et al. Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 4: Variation of the basic structure. Arch Pharm (Weinheim) 2000;333:181-8. (Pubitemid 30435559)
116. Ching LM, Joseph WR, Baguley BC. Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Biochem Pharmacol 1992;44:192-5.
117. Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, et al. Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6- Dimethylxan -thenone-4-Acetic Acid Induces an Effective CD8+ T- Cell Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma. Cancer Res 2005;65:11752-61. (Pubitemid 41821737)
118. Phillips RM. Inhibition of DT-diaphorase (NAD (P) H: quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone- 4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Biochem Pharmacol 1999;58:303-10. (Pubitemid 29255949)
119. Baguley BC, Cole G, Thomsen LL, Li Z. Serotonin involvement in the antitumour and Host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone- 4-acetic acid. Cancer Chemother Pharmacol 1993;33:77-81. (Pubitemid 23336505)
120. Carrara M, Zampiron A, Barbera M, Caputo A, Bisi A, Gobbi S, et al. Mono or di- fluorinated analogues of flavone-8-acetic acid: synthesis and in vitro biological activity. Anticancer Res 2005;25:1179-85. (Pubitemid 40546895)
121. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999;17: 313-20. (Pubitemid 30037961)
122. Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann JT, Bokemeyer C. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs 2005;23:205-11. (Pubitemid 40684945)
123. Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000;9:2903-11.
124. Wang HK. The therapeutic potential of flavonoids. Expert Opin Investig Drugs 2000;9:2103-19.
125. Xie WD, Li PL, Jia ZJ. A new flavone glycoside and other constituents from Carduus crispus. Pharmazie 2005;60:233-6.
126. Yoshimizu N, Otani Y, Saikawa Y, Kubota T, Yoshida M, Furukawa T, et al. Anti-tumour effects of nobiletin, a citrus flavonoid, on gastric cancer include: antiproliferative effects, induction of apoptosis and cell cycle deregulation. Aliment Pharmacol Ther 2004;20:95S-101S.
127. Giacomelli S, Gallo D, Apollonio P, Ferlini C, Distefano M, Morazzoni P, et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci 2002;70:1447-59. (Pubitemid 34159100)
128. Androutsopoulos VP, Mahale S, Arroo RR, Potter G. Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation. Oncol Rep 2009;21:1525-8.
129. Huang H, Jia Q, Ma J, Qin G, Chen Y, Xi Y, et al. Discovering novel quercetin-3-O- amino acid-esters as a new class of Src tyrosine kinase inhibitors. Eur J Med Chem 2009;44:1982-8.
130. Rybarczyk PAJ, Małecka M, Glinka ̈, Ochocki J. Trans-bis (3-aminoflavone- kappa 2N, O) bis (perchlorato-kappaO) copper (II), a new potential antitumour agent. Acta Crystallogr C 2007;63:410-2.
131. Carli CB, De Matos DC, Lopes FC, Maia DC, Dias MB, Sannomiya M, et al. Isolated flavonoids against mammary tumour cells LM2. Z Naturforsch C. 2009;64:32-6.